Yuanzhi Lao (Y Lao)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2019
Publications (10 Years): 4

Top Topics

Signaling Pathway

Squamous Cell Carcinoma

Long Noncoding Rna

Advanced Non Small Cell Lung Cancer

Top Venues

Cell death & disease

Qilu Pharmaceutical Co Ltd

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Qilu Pharmaceutical Co Ltd

China

Deriector :: Target Validation

Publications

Juan Zhang, Zhaoqing Zheng, Man Wu, Li Zhang, Jing Wang, Wenwei Fu, Naihan Xu, Zhili Zhao, Yuanzhi Lao, Hong-Xi Xu
The natural compound neobractatin inhibits tumor metastasis by upregulating the RNA-binding-protein MBNL2. Cell death & disease 10 (8) (2019)
Linfeng Xu, Xiaoxiao Meng, Naihan Xu, Wenwei Fu, Hongsheng Tan, Li Zhang, Qianjun Zhou, Jianan Qian, Shiwei Tu, Xueting Li, Yuanzhi Lao, Hongxi Xu
Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth. Cell death & disease 9 (3) (2018)
Yang Li, Zhichao Xi, Xiaoqiong Chen, Shuangfan Cai, Chen Liang, Zhen Wang, Yingyi Li, Hongsheng Tan, Yuanzhi Lao, Hongxi Xu
Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways. Cell death & disease 9 (5) (2018)
L Liu, Jie He, X Wei, G Wan, Yuanzhi Lao, W Xu, Z Li, H Hu, Z Hu, X Luo, J Wu, W Xie, Y Zhang, N Xu
MicroRNA-20a-mediated loss of autophagy contributes to breast tumorigenesis by promoting genomic damage and instability. Oncogene 36 (42) (2017)